BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults

Reuters12-13

Dec 13 (Reuters) - EMA'S CHMP:

EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITY
EMA'S CHMP: SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJARO
EMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA (ACORAMIDIS)
EMA'S CHMP: KAVIGALE (SIPAVIBART) RECEIVED POSITIVE OPINION
EMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIA
EMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG (BELZUTIFAN)

Source text: [ID:]

Further company coverage: LLY.N

((Reuters.Briefs@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491326161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-13 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491326161","market":"us","top_or_hot":-1,"title":"BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults</title></head><body><p><span>Dec 13 (Reuters)</span><span> - </span>EMA'S CHMP: </p><ul><li><p>EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITY</p></li><li><p>EMA'S CHMP:  SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJARO</p></li><li><p>EMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA (ACORAMIDIS)</p></li><li><p>EMA'S CHMP: KAVIGALE (SIPAVIBART) RECEIVED POSITIVE OPINION</p></li><li><p>EMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIA</p></li><li><p>EMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG (BELZUTIFAN)</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>LLY.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-13 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0F2:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese AdultsDec 13 (Reuters) - EMA'S CHMP: EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0F2:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0661504455.SGD","symbol_name":"Blackrock Global Equity Income A5 SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0F2:1","article_id":"2491326161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491326161","pubTimestamp":1734090488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese AdultsDec 13  - EMA'S CHMP: EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITYEMA'S CHMP:  SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJAROEMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA EMA'S CHMP: KAVIGALE  RECEIVED POSITIVE OPINIONEMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIAEMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG Source text: [ID:]Further company coverage: LLY.N ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","SG9999014559.SGD":"United Income Focus Trust Dis SGD","GERN":"杰龙","AZN.UK":"阿斯利康制药","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","MRK":"默沙东","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LLY":"礼来","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BBIO":"BridgeBio Pharma, Inc.","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0784385840.USD":"Blackrock Global Multi-Asset Income A2 USD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU0757432116.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK5011":"制药","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","03165":"华夏欧优股对冲","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2114397693.USD":"BGF EUROPEAN EQUITY INCOME \"A\" (USDHDG) INC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD"},"translate_title":"简介-EMA的CHMP表示肥胖成人OSA无需单独使用Mounjaro适应症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN.UK":0.9,"BBIO":0.9,"GERN":0.9,"LLY":0.9,"MRK":0.9,"03165":0.6},"content_text":"BRIEF-EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese AdultsDec 13 (Reuters) - EMA'S CHMP: EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN ADULTS WITH OBESITYEMA'S CHMP:  SEPARATE INDICATION FOR TREATMENT OF MODERATE TO SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJAROEMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA (ACORAMIDIS)EMA'S CHMP: KAVIGALE (SIPAVIBART) RECEIVED POSITIVE OPINIONEMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF ADULTS WITH TRANSFUSION-DEPENDENT ANAEMIAEMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR WELIREG (BELZUTIFAN)Source text: [ID:]Further company coverage: LLY.N ((Reuters.Briefs@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491326161"}